At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Vonafexor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
In Brief
A Phase 2 clinical trial evaluating Vonafexor and Placebo for Non-alcoholic Steatohepatitis. Completed, enrolled 120 participants across 42 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis
CountriesBelgium, France, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionJun 2021
Study CompletionJul 2021
TodayJul 2026
First PostedJan 22, 2019
Enrollment StartJan 30, 2019
Primary CompletionJun 16, 2021
Study CompletionJul 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.4 years ago
Interventions
Vonafexordrug
Oral tablets
Placeboother
Oral tablets